Diagnosis and treatment of bacterial diarrhea

James V. Lawler, Mark R. Wallace

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Diarrheal illness caused by bacterial pathogens is a global health problem and remains one of the most common complaints prompting patients to seek medical care. Strategies to increase the yield of stool culture and new rapid diagnostic tests can improve diagnostic ability. Emerging antimicrobial resistance among the common bacterial causes of diarrhea has made treatment more challenging. Emerging fluoroquinolone resistance is a particular concern. Recent studies of rifaximin, a nonabsorbed antibiotic for the treatment of bacterial diarrhea, have shown favorable results. Rifaximin may represent a much-needed addition to the armamentarium against bacterial agents.

Original languageEnglish (US)
Pages (from-to)287-294
Number of pages8
JournalCurrent gastroenterology reports
Volume5
Issue number4
DOIs
StatePublished - Aug 2003

Fingerprint

rifaximin
Diarrhea
Fluoroquinolones
Routine Diagnostic Tests
Anti-Bacterial Agents
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Diagnosis and treatment of bacterial diarrhea. / Lawler, James V.; Wallace, Mark R.

In: Current gastroenterology reports, Vol. 5, No. 4, 08.2003, p. 287-294.

Research output: Contribution to journalReview article

Lawler, James V. ; Wallace, Mark R. / Diagnosis and treatment of bacterial diarrhea. In: Current gastroenterology reports. 2003 ; Vol. 5, No. 4. pp. 287-294.
@article{55ca6df2506e45edb01304f6cc600b6f,
title = "Diagnosis and treatment of bacterial diarrhea",
abstract = "Diarrheal illness caused by bacterial pathogens is a global health problem and remains one of the most common complaints prompting patients to seek medical care. Strategies to increase the yield of stool culture and new rapid diagnostic tests can improve diagnostic ability. Emerging antimicrobial resistance among the common bacterial causes of diarrhea has made treatment more challenging. Emerging fluoroquinolone resistance is a particular concern. Recent studies of rifaximin, a nonabsorbed antibiotic for the treatment of bacterial diarrhea, have shown favorable results. Rifaximin may represent a much-needed addition to the armamentarium against bacterial agents.",
author = "Lawler, {James V.} and Wallace, {Mark R.}",
year = "2003",
month = "8",
doi = "10.1007/s11894-003-0065-z",
language = "English (US)",
volume = "5",
pages = "287--294",
journal = "Current Gastroenterology Reports",
issn = "1522-8037",
publisher = "Current Medicine Group",
number = "4",

}

TY - JOUR

T1 - Diagnosis and treatment of bacterial diarrhea

AU - Lawler, James V.

AU - Wallace, Mark R.

PY - 2003/8

Y1 - 2003/8

N2 - Diarrheal illness caused by bacterial pathogens is a global health problem and remains one of the most common complaints prompting patients to seek medical care. Strategies to increase the yield of stool culture and new rapid diagnostic tests can improve diagnostic ability. Emerging antimicrobial resistance among the common bacterial causes of diarrhea has made treatment more challenging. Emerging fluoroquinolone resistance is a particular concern. Recent studies of rifaximin, a nonabsorbed antibiotic for the treatment of bacterial diarrhea, have shown favorable results. Rifaximin may represent a much-needed addition to the armamentarium against bacterial agents.

AB - Diarrheal illness caused by bacterial pathogens is a global health problem and remains one of the most common complaints prompting patients to seek medical care. Strategies to increase the yield of stool culture and new rapid diagnostic tests can improve diagnostic ability. Emerging antimicrobial resistance among the common bacterial causes of diarrhea has made treatment more challenging. Emerging fluoroquinolone resistance is a particular concern. Recent studies of rifaximin, a nonabsorbed antibiotic for the treatment of bacterial diarrhea, have shown favorable results. Rifaximin may represent a much-needed addition to the armamentarium against bacterial agents.

UR - http://www.scopus.com/inward/record.url?scp=0042330171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042330171&partnerID=8YFLogxK

U2 - 10.1007/s11894-003-0065-z

DO - 10.1007/s11894-003-0065-z

M3 - Review article

C2 - 12864958

AN - SCOPUS:0042330171

VL - 5

SP - 287

EP - 294

JO - Current Gastroenterology Reports

JF - Current Gastroenterology Reports

SN - 1522-8037

IS - 4

ER -